Oncology Innovation Has Produced Major Drop in Pediatric Cancer Deaths

One of the toughest parts of working in the biotechnology industry is the likelihood that you will eventually pour your heart and soul into a project, work long hours, do everything right, advance promising science, raise loads of capital, even see patients helped in clinical trials … yet, ultimately, fail to commercialize a new medicine because of a safety or efficacy issue.
Ninety percent of programs in the clinic do not make it to the pharmacy shelf. The approval of biomedical breakthr